For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
REGULATORY
Revamped Sakigake Pricing Premium to Grant Maximum Premium Rate of 20%: Chuikyo Subcommittee
The revamped version of a dormant pricing premium designed to reward the development of first-in-class drugs in Japan is likely to carry a maximum premium rate of 20%, up from the current 10%, as no member of the Central Social…
To read the full story
Related Article
- MHLW Calls for 50% Pricing Rule for First Generics, 40% Rule for 10-Plus Oral Generics
December 4, 2015
- New HTA Scheme Should Only Cover Big-Selling Products Given Big Premiums: JPMA Chief
December 4, 2015
- Chuikyo Subcommittee Agrees on Scope of “Essential Drugs”; Trial Run of Innovation Premium to Continue
December 4, 2015
- Chuikyo Basically OKs 2-Tiered Re-Pricing for Huge Seller Drugs; Sovaldi Almost Certain to Face Cut
December 3, 2015
- Generic Replacement Rate Applied to Z2 Rule to Be Hiked 10%
December 3, 2015
REGULATORY
- Japan Partially Eases Rule for Use of Abortion Pill Mefeego
December 2, 2024
- MOF Panel Wants Prioritized Budgeting for Drug Costs: Subcommittee Acting Chair
December 2, 2024
- MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
- Japan to Require Drug Makers to Set Up Legal Post of “Stable Supply Manager”
November 29, 2024
- Japan Set to Put Up 100 Billion Yen to Support Pharma under Economic Package
November 29, 2024
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…